The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen

Emily J Henderson; Stephen R Lord; Jacqueline Ct Close; Andrew D Lawrence; Alan Whone; Yoav Ben-Shlomo

doi:10.1186/1471-2377-13-188

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen

Emily J Henderson, Stephen R Lord, Jacqueline Ct Close, Andrew D Lawrence, Alan Whone, Yoav Ben-Shlomo

Research output: Contribution to journal › Article (Academic Journal) › peer-review

18 Citations (Scopus)

Abstract

Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.

Original language	English
Pages (from-to)	188
Journal	BMC Neurology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/1471-2377-13-188
Publication status	Published - 2013

Access to Document

10.1186/1471-2377-13-188

Fingerprint Dive into the research topics of 'The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen'. Together they form a unique fingerprint.

Cite this

Henderson, E. J., Lord, S. R., Close, J. C., Lawrence, A. D., Whone, A., & Ben-Shlomo, Y. (2013). The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC Neurology, 13(1), 188. https://doi.org/10.1186/1471-2377-13-188

Henderson, Emily J ; Lord, Stephen R ; Close, Jacqueline Ct ; Lawrence, Andrew D ; Whone, Alan ; Ben-Shlomo, Yoav. / The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. In: BMC Neurology. 2013 ; Vol. 13, No. 1. pp. 188.

@article{46c658d084c14dafaada5d7b218fc456,

title = "The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen",

abstract = "Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.",

author = "Henderson, {Emily J} and Lord, {Stephen R} and Close, {Jacqueline Ct} and Lawrence, {Andrew D} and Alan Whone and Yoav Ben-Shlomo",

year = "2013",

doi = "10.1186/1471-2377-13-188",

language = "English",

volume = "13",

pages = "188",

journal = "BMC Neurology",

issn = "1471-2377",

publisher = "BioMed Central",

number = "1",

}

Henderson, EJ, Lord, SR, Close, JC, Lawrence, AD, Whone, A & Ben-Shlomo, Y 2013, 'The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen', BMC Neurology, vol. 13, no. 1, pp. 188. https://doi.org/10.1186/1471-2377-13-188

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. / Henderson, Emily J; Lord, Stephen R; Close, Jacqueline Ct; Lawrence, Andrew D; Whone, Alan ; Ben-Shlomo, Yoav.

In: BMC Neurology, Vol. 13, No. 1, 2013, p. 188.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen

AU - Henderson, Emily J

AU - Lord, Stephen R

AU - Close, Jacqueline Ct

AU - Lawrence, Andrew D

AU - Whone, Alan

AU - Ben-Shlomo, Yoav

PY - 2013

Y1 - 2013

N2 - Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.

AB - Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.

U2 - 10.1186/1471-2377-13-188

DO - 10.1186/1471-2377-13-188

M3 - Article (Academic Journal)

C2 - 24299497

VL - 13

SP - 188

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

ER -

Henderson EJ, Lord SR, Close JC, Lawrence AD, Whone A , Ben-Shlomo Y. The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC Neurology. 2013;13(1):188. https://doi.org/10.1186/1471-2377-13-188